
Hyderabad doctor helps secure affordable rare disease medication for seven children
Illustration: NexVani Media
A Hyderabad doctor has led an initiative to provide affordable tiratricol to seven children suffering from a rare genetic disorder, significantly reducing treatment costs.
A dedicated Hyderabad doctor has successfully spearheaded an initiative to provide life-changing medication to children suffering from Allan-Herndon-Dudley syndrome (AHDS). This rare genetic disorder, also known as MCT8 deficiency, affects the transport of thyroid hormones into brain cells. For seven families across India, the arrival of the medication tiratricol on November 30 marks a turning point in managing their children's health.
Dr. Sivaranjani Santosh, a paediatrician based in Hyderabad, initiated the effort after witnessing the extreme financial burden faced by families. The commercial version of tiratricol is prohibitively expensive, costing between โน4.68 crore and โน9 crore per child annually. One parent, Pavitra Sirolkar, previously struggled to source a single monthโs supply from Germany for approximately โน12 lakh to โน13 lakh.
Collaborative medical solution
To overcome these costs, Dr. Sivaranjani collaborated with Access to Medicines India and the Netherlands-based Pharmaceutical Accountability Foundation (PAF). By utilizing pharmaceutical compounding at Transvaal Pharmacy in The Hague, the team developed a formulation that costs roughly โน2.5 lakh per child for a full year. The total cost of โน15.08 lakh for all seven children was covered through a combination of local fundraising and support from the PAF in the Netherlands.
Since the compounded medicine has a six-month shelf life, it will be imported in two batches to ensure the children receive a consistent, year-long supply. The group of patients includes children previously identified by doctors at Christian Medical College, Vellore, and a child identified following a social media appeal launched by Dr. Sivaranjani in September.
A Hyderabad doctor enabled free treatment for seven children by reducing rare disease drug costs significantly.
While this initiative provides immediate relief, Dr. Sivaranjani emphasizes that importing medication is not a sustainable long-term solution. She intends to work with the Union government and various organizations to explore the possibility of compounding this essential medicine within India. This shift would ensure that the treatment remains accessible to a larger number of children suffering from this condition.
Why it matters
This development is critical because it transforms a previously inaccessible treatment into a viable option for Indian families. By lowering the annual cost per patient from crores to lakhs, the initiative demonstrates how international collaboration and pharmaceutical compounding can bypass extreme commercial pricing to save lives.
For the seven families involved, this means a full year of medical security. More broadly, the effort highlights a potential pathway for making rare disease therapies affordable in India, offering hope to other patients who currently face similar financial barriers to essential care.
Sources
More like this

NSW mother ignored medical advice for twin home birth, inquest hears

Shift Toward Direct Cremation Funerals Continues Following Pandemic

Weight-loss drugs used in nearly one in 10 homes in Great Britain, study finds

